Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries
暂无分享,去创建一个
P. Ferenci | D. Back | S. Bourgeois | P. Buggisch | S. Norris | M. Curescu | D. Larrey | F. Marra | H. Kleine | P. Dorr | M. Charafeddine | Eric D Crown | M. Bondin | R. Flisiak